A string of ASX-listed drug developers is due to release company-making – or breaking – pivotal clinical study results in coming months.
Good morning! Here’s everything you need to know before the ASX flings open its doors and begins trading today.
The funding comes as a $5m share placement and a further $10m investment in return for a 2% net smelter royalty on future production.
Australian miners – and scientists – are at the forefront of a new world order for a reliable supply of rare earths.
Helium shortages are squeezing chipmakers and Adisyn is betting on redesigning chips to need less of it.
